Mette Vesterhus

List of Publications by Year
in descending order

57 papers	2,411 citations	218677 26 h-index	206112 48 g-index
59 all docs	59 docs citations	59 times ranked	3428 citing authors

#	Article	IF	Citations
1	Primary sclerosing cholangitis â€“ a comprehensive review. Journal of Hepatology, 2017, 67, 1298-1323.	3.7	538
2	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut, 2017, 66, 611-619.	12.1	308
3	Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunology, 2016, 9, 1455-1465.	6.0	130
4	Enhanced liver fibrosis score predicts transplantâ€free survival in primary sclerosing cholangitis. Hepatology, 2015, 62, 188-197.	7.3	106
5	Lack of pancreatic body and tail in HNF1B mutation carriers. Diabetic Medicine, 2008, 25, 782-787.	2.3	98
6	Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning. Hepatology, 2020, 71, 214-224.	7.3	90
7	Diabetes and Pancreatic Exocrine Dysfunction Due to Mutations in the Carboxyl Ester Lipase Gene-Maturity Onset Diabetes of the Young (CEL-MODY). Journal of Biological Chemistry, 2011, 286, 34593-34605.	3.4	80
8	Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 282-301.	3.7	75
9	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. Gastroenterology, 2021, 160, 1784-1798.e0.	1.3	69
10	Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut, 2017, 66, 137-144.	12.1	59
11	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. Journal of Hepatology, 2020, 73, 1496-1506.	3.7	55
12	Enhanced liver fibrosis test predicts transplantâ€free survival in primary sclerosing cholangitis, a multiâ€centre study. Liver International, 2017, 37, 1554-1561.	3.9	54
13	Novel serum and bile protein markers predict primary sclerosing cholangitis disease severity and prognosis. Journal of Hepatology, 2017, 66, 1214-1222.	3.7	51
14	Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis. Liver International, 2019, 39, 371-381.	3.9	51
15	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. Journal of Gastroenterology, 2020, 55, 588-614.	5.1	49
16	Normal Liver Stiffness Values in Children. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 706-712.	1.8	42
17	Carboxyl-Ester Lipase Maturity-Onset Diabetes of the Young Is Associated With Development of Pancreatic Cysts and Upregulated MAPK Signaling in Secretin-Stimulated Duodenal Fluid. Diabetes, 2014, 63, 259-269.	0.6	38
18	InÂVitro Comparison of Five Different Elastography Systems for Clinical Applications, Using Strain and Shear Wave Technology. Ultrasound in Medicine and Biology, 2016, 42, 2572-2588.	1.5	37

#	Article	IF	Citations
19	Liver elasticity in healthy individuals by two novel shear-wave elastography systemsâ€"Comparison by age, gender, BMI and number of measurements. PLoS ONE, 2018, 13, e0203486.	2.5	37
20	Repeatability of shear wave elastography in liver fibrosis phantomsâ€"Evaluation of five different systems. PLoS ONE, 2018, 13, e0189671.	2.5	37
21	Elevated interleukinâ€8 in bile of patients with primary sclerosing cholangitis. Liver International, 2016, 36, 1370-1377.	3.9	34
22	The role of pancreatic imaging in monogenic diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 148-159.	9.6	32
23	Reduced Pancreatic Volume in Hepatocyte Nuclear Factor 1A-Maturity-Onset Diabetes of the Young. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3505-3509.	3.6	29
24	Antineutrophil antibodies define clinical and genetic subgroups in primary sclerosing cholangitis. Liver International, 2017, 37, 458-465.	3.9	28
25	Assessing Liver Stiffness by 2-D Shear Wave Elastography in a Healthy Cohort. Ultrasound in Medicine and Biology, 2018, 44, 332-341.	1.5	28
26	Serological markers of extracellular matrix remodeling predict transplantâ€free survival in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2018, 48, 179-189.	3.7	28
27	Pancreatic Function in Carboxyl-Ester Lipase Knockout Mice. Pancreatology, 2010, 10, 467-476.	1.1	26
28	Pancreatic Exocrine Dysfunction in Maturity-Onset Diabetes of the Young Type 3. Diabetes Care, 2008, 31, 306-310.	8.6	25
29	Elevated trimethylamineâ€N â€oxide (TMAO) is associated with poor prognosis in primary sclerosing cholangitis patients with normal liver function. United European Gastroenterology Journal, 2017, 5, 532-541.	3.8	20
30	Absence of Diabetes and Pancreatic Exocrine Dysfunction in a Transgenic Model of Carboxyl-Ester Lipase-MODY (Maturity-Onset Diabetes of the Young). PLoS ONE, 2013, 8, e60229.	2.5	20
31	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	4.4	18
32	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	3.9	15
33	Neurological Features and Enzyme Therapy in Patients With Endocrine and Exocrine Pancreas Dysfunction Due to CEL Mutations. Diabetes Care, 2008, 31, 1738-1740.	8.6	14
34	Ultrasound and Point Shear Wave Elastography in Livers of Patients with Primary Sclerosing Cholangitis. Ultrasound in Medicine and Biology, 2016, 42, 2146-2155.	1.5	14
35	Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis. European Journal of Clinical Investigation, 2019, 49, e13088.	3.4	14
36	Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. Clinical and Translational Gastroenterology, 2021, 12, e00315.	2.5	10

#	Article	IF	Citations
37	Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis. Scientific Reports, 2019, 9, 8450.	3.3	8
38	Associations of neopterin and kynurenineâ€“tryptophan ratio with survival in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2021, 56, 443-452.	1.5	8
39	Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF. JHEP Reports, 2021, 3, 100328.	4.9	8
40	Comprehensive assessment of ECM turnover using serum biomarkers establishes PBC as a high-turnover autoimmune liver disease. JHEP Reports, 2021, 3, 100178.	4.9	7
41	Liver Elastography in Primary Sclerosing Cholangitis Patients Using Three Different Scanner Systems. Ultrasound in Medicine and Biology, 2020, 46, 1854-1864.	1.5	5
42	Highly Increased Levels of Inter-Î±-inhibitor Heavy Chain 4 (ITIH4) in Autoimmune Cholestatic Liver Diseases. Journal of Clinical and Translational Hepatology, 2022, 10, 796-802.	1.4	3
43	Serological Biomarkers of Extracellular Matrix Remodeling Predict Transplant-Free Survival in Primary Sclerosing Cholangitis Patients. Journal of Hepatology, 2016, 64, S199.	3.7	2
44	Reply to: â€œBoth tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitisâ€• Journal of Hepatology, 2021, 74, 755-756.	3.7	2
45	Liver Elastography in Healthy Children Using Three Different Systems â€“ How Many Measurements Are Necessary?. Ultraschall in Der Medizin, 2022, 43, 488-497.	1.5	2
46	O133 NOVEL PROTEIN MARKERS IDENTIFIED IN BILE AND SERUM ARE ASSOCIATED WITH A DIAGNOSIS OF PRIMARY SCLEROSING CHOLANGITIS, DISEASE SEVERITY, AND TRANSPLANT-FREE SURVIVAL. Journal of Hepatology, 2014, 60, S55-S56.	3.7	1
47	O082 : The gut microbiota in primary sclerosing cholangitis differs from that of healthy controls and ulcerative colitis patients without biliary disease. Journal of Hepatology, 2015, 62, S231-S232.	3.7	1
48	P1174 : Microbiota-dependent marker trimethylamine-N-oxide (TMAO) is associated with the severity of primary sclerosing cholangitis. Journal of Hepatology, 2015, 62, S793-S794.	3.7	1
49	Autoreactive Iga Antibodies against the Pancreatic Major Glycoprotein 2 are Associated with Primary Sclerosing Cholangitis and Related Biliary Tract Cancer. Journal of Hepatology, 2016, 64, S647.	3.7	1
50	Prognostic biomarkers and surrogate end points in <scp>PSC</scp>. Liver International, 2016, 36, 1748-1751.	3.9	1
51	Point Shear Wave Elastography and the Effect of Physical Exercise, Alcohol Consumption, and Respiration in Healthy Adults. Ultrasound International Open, 2020, 06, E54-E61.	0.6	1
52	Controlled Attenuation Parameter in Healthy Individuals Aged 8â€“70 Years. Ultrasound International Open, 2021, 07, E6-E13.	0.6	1
53	P363 ENHANCED LIVER FIBROSIS SCORE PREDICTS TRANSPLANT-FREE SURVIVAL IN PSC INDEPENDENTLY OF THE MAYO RISK SCORE. Journal of Hepatology, 2014, 60, S188.	3.7	0
54	PWE-096ÂNon-invasive assessment of disease severity in primary sclerosing cholangitis (psc): clinical scores, transient elastography (te) and the enhanced liver fibrosis (elf) test: Abstract PWE-096 Table 1. Gut, 2015, 64, A254.1-A254.	12.1	0

#	Article	IF	Citations
55	Biliary Tract Cancer with or without Primary Sclerosing Cholangitis is Associated with a Raised Enhanced Liver Fibrosis Test Result Compared with PSC Alone. Journal of Hepatology, 2016, 64, S722-S723.	3.7	0
56	Normal liver elasticity values in a healthy population, by age and gender, for two novel elastography systems. Journal of Hepatology, 2018, 68, S645-S646.	3.7	0
57	THU-002-Macrophage activation marker neopterin predicts liver transplantation-free survival in primary sclerosing cholangitis. Journal of Hepatology, 2019, 70, e161.	3.7	0